Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D001172 | Arthritis, Rheumatoid NIH | 0.30 |
D001168 | Arthritis NIH | 0.26 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001370 | Rheumatoid arthritis HPO | 0.32 |
HP:0001369 | Arthritis HPO | 0.27 |
Navigate: Correlations HPO
There is one clinical trial.
Background: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged as a potentially life-threatening disease in Wuhan, China, at the end of 2019. Since then, it has spread to almost 200 countries and infection rates are rapidly accelerating. Overactivation of T cells resulting in immune dysfunction, dysfunction of the renin angiotensin system, and antibody-dependent enhancement are thought to contribute to the cytokine storm that results in acute respiratory distress syndrome (ARDS), culminating in death. In addition to causing respiratory symptoms, SARS-CoV-2 can cause diarrhea and has been isolated from the stool. SARS-CoV-2 binds to Angiotensin-converting enzyme 2 (ACE2) on lung alveolar type 2 cells, but ACE2 is also expressed in the absorptive enterocytes from the ileum and colon. The diarrhea may be caused by increased intestinal permeability due to binding of these receptors by the SARS-CoV-2. Thus, an intervention to attenuate this cytokine storm may improve clinical outcomes in people with COVID-19. One such intervention is oral administration of serum bovine immunoglobulins, which decreases interleukin-6 (IL-6) levels safely with minimal side effects. Animal and human clinical studies have shown dietary supplementation with oral immunoglobulins improves mucosal immunity, specifically respiratory/pulmonary and GI mucosa, and decreases systemic inflammation, reducing the symptoms and severity of pulmonary inflammation and viral infections. Hypothesis: Dietary supplementation with EnteraGam® will decrease IL-6 levels and prevent disease progression in SARS-CoV-2 infected individuals. Objectives: To evaluate the effectiveness of the oral nutritional therapy EnteraGam® (serum-derived bovine immunoglobulin/protein isolate) to prevent disease progression of COVID-19 and to decrease IL-6 levels as compared to standard of care in subjects with COVID-19. Methods: Randomized open-label clinical study evaluating the effectiveness of EnteraGam® 10.0 g BID (every 12 hours) added to standard of care, as compared to standard of care alone, in subjects with COVID-19.
Description: Variation of IL-6 levels measured in plasma
Measure: Change in plasma IL-6 levels Time: From baseline to Week 2Description: Percentage of patients with COVID-19 who have disease progression by Week 2, defined as: For outpatients, return to emergency department for COVID-19 related manifestations or worsening of ≥1 level on the World Health Organization (WHO) 9-point ordinal scale. For inpatients, worsening of ≥1 level on the WHO 9-point ordinal scale.
Measure: COVID-19 disease progression by Week 2 Time: From baseline to Week 2Description: Variation of dyspnea presentation at Week 2 compared to baseline, assessed by daily symptoms questionnaire
Measure: Change in dyspnea Time: At Week 2Description: Variation of diarrhea presentation at Week 2 compared to baseline, assessed by daily symptoms questionnaire
Measure: Change in diarrhea Time: At Week 2Description: Variation of fever presentation at Week 2 compared to baseline
Measure: Change in fever Time: At Week 2Description: Variation of neutrophil count at Week 2 compared to baseline
Measure: Change in neutrophil count Time: At Week 2Description: Variation of lymphocyte count at Week 2 compared to baseline
Measure: Change in lymphocyte count Time: At Week 2Description: Variation of neutrophil/lymphocyte ratio at Week 2 compared to baseline
Measure: Change in neutrophil/lymphocyte ratio Time: At Week 2Description: Variation of platelet count at Week 2 compared to baseline
Measure: Change in platelet count Time: At Week 2Description: Variation of C-reactive protein levels at Week 2 compared to baseline
Measure: Change in C-reactive protein Time: At Week 2Description: Variation of ferritin levels at Week 2 compared to baseline
Measure: Change in ferritin Time: At Week 2Description: Variation of D-dimer levels at Week 2 compared to baseline
Measure: Change in D-dimer Time: At Week 2Description: Variation of Aspartate Transaminase (AST/GOT) levels at Week 2 compared to baseline
Measure: Change in AST Time: At Week 2Description: Variation of Alanine Transaminase (ALT/GPT) levels at Week 2 compared to baseline
Measure: Change in ALT Time: At Week 2Description: Time elapsed between baseline and disease progression, defined as: For outpatients, return to emergency department for COVID-19 related manifestations or worsening of ≥1 level on the WHO 9-point ordinal scale. For inpatients, worsening of ≥1 level on the WHO 9-point ordinal scale.
Measure: Time to worsening clinical status Time: From baseline to Week 2Description: Incidence of serious and non-serious adverse events.
Measure: Incidence of Adverse Events Time: From baseline to Week 2Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports